Citius Pharmaceuticals, Inc. Deferred Offering Costs
Citius Pharmaceuticals, Inc. (CTXR) had Deferred Offering Costs of $20.00 thousand as of 2017-06-30, per its 10-Q filed 2017-08-14.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2017-12-13
- 2017-06-30: Deferred Offering Costs $20.00K.
- 2016-09-30: Deferred Offering Costs $64.80K.
- 2013-12-31: Deferred Offering Costs $25.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2017-06-30 | $20.00K 10-Q · filed 2017-08-14 |
| 2016-09-30 | $64.80K 10-K · filed 2017-12-13 |
| 2013-12-31 | $25.00K 10-KT · filed 2014-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |